Your browser is no longer supported. Please, upgrade your browser.
CRBP Corbus Pharmaceuticals Holdings, Inc. daily Stock Chart
CRBP [NASD]
Corbus Pharmaceuticals Holdings, Inc.
Index- P/E- EPS (ttm)-1.13 Insider Own0.50% Shs Outstand69.27M Perf Week-3.40%
Market Cap558.18M Forward P/E- EPS next Y-1.54 Insider Trans7.31% Shs Float63.84M Perf Month5.06%
Income-74.90M PEG- EPS next Q-0.39 Inst Own51.00% Short Float20.93% Perf Quarter33.57%
Sales36.00M P/S15.51 EPS this Y-14.50% Inst Trans0.53% Short Ratio10.01 Perf Half Y21.33%
Book/sh0.33 P/B23.27 EPS next Y1.30% ROA-112.30% Target Price- Perf Year15.14%
Cash/sh0.64 P/C11.98 EPS next 5Y- ROE-282.90% 52W Range3.29 - 8.78 Perf YTD40.66%
Dividend- P/FCF- EPS past 5Y-61.90% ROI- 52W High-12.52% Beta1.45
Dividend %- Quick Ratio1.60 Sales past 5Y- Gross Margin- 52W Low133.43% ATR0.47
Employees141 Current Ratio1.60 Sales Q/Q-5.30% Oper. Margin- RSI (14)50.48 Volatility4.64% 6.37%
OptionableYes Debt/Eq0.02 EPS Q/Q-0.60% Profit Margin- Rel Volume0.72 Prev Close7.68
ShortableYes LT Debt/Eq0.00 EarningsMay 11 BMO Payout- Avg Volume1.33M Price7.68
Recom1.60 SMA20-1.93% SMA504.79% SMA20031.89% Volume0 Change0.00%
Jul-07-20Initiated ROTH Capital Buy $40
Jun-17-20Initiated BTIG Research Buy $22
Mar-26-20Initiated Nomura Buy $12
Apr-05-19Initiated Jefferies Buy
Mar-20-19Initiated Oppenheimer Outperform $28
Jan-11-19Reiterated Cantor Fitzgerald Overweight $36 → $38
Dec-26-18Initiated H.C. Wainwright Buy $24
Dec-07-18Initiated RBC Capital Mkts Outperform $23
Oct-24-18Initiated B. Riley FBR Buy $22
Jan-19-18Initiated Raymond James Outperform $24
Dec-14-17Reiterated Cantor Fitzgerald Overweight $24 → $28
Nov-08-17Reiterated Noble Financial Buy $16 → $20
Sep-29-17Resumed Noble Financial Buy $16
Mar-30-17Reiterated Cantor Fitzgerald Overweight $17 → $24
Nov-15-16Reiterated JMP Securities Mkt Outperform $9 → $20
Nov-11-16Reiterated Noble Financial Buy $19
Oct-05-16Initiated Cantor Fitzgerald Buy $17
Sep-08-15Initiated JMP Securities Mkt Outperform $6
Jul-08-20 08:05AM  
Jul-05-20 09:58PM  
Jun-29-20 08:05AM  
Jun-22-20 08:05AM  
Jun-18-20 10:56AM  
08:51AM  
Jun-01-20 09:00AM  
08:05AM  
May-28-20 06:53AM  
May-27-20 08:05AM  
May-22-20 08:05AM  
May-18-20 03:09AM  
May-15-20 12:00PM  
08:05AM  
May-14-20 09:30AM  
May-11-20 09:55AM  
07:05AM  
May-04-20 08:05AM  
Apr-30-20 04:15PM  
Apr-29-20 08:05AM  
Apr-28-20 07:05AM  
Apr-02-20 08:58AM  
04:00AM  
Mar-14-20 08:52AM  
Mar-12-20 08:55AM  
07:05AM  
06:30AM  
Mar-10-20 08:05AM  
07:14AM  
Mar-05-20 08:05AM  
Mar-03-20 12:30PM  
Feb-11-20 04:01PM  
Feb-10-20 08:58AM  
Feb-07-20 09:02AM  
Feb-06-20 04:01PM  
Jan-31-20 03:45PM  
Jan-25-20 08:09AM  
Dec-19-19 08:07AM  
Dec-17-19 04:07PM  
Dec-09-19 08:05AM  
Nov-18-19 08:17AM  
Nov-16-19 09:40PM  
Nov-12-19 08:05AM  
07:20AM  
Nov-11-19 08:05AM  
Nov-07-19 11:15AM  
07:05AM  
Nov-05-19 01:00PM  
Nov-04-19 08:05AM  
Nov-01-19 12:08PM  
Oct-13-19 10:06AM  
Oct-03-19 08:05AM  
Oct-01-19 09:03AM  
Sep-13-19 07:21AM  
Aug-16-19 12:00AM  
Aug-14-19 08:32AM  
01:35AM  
Aug-12-19 12:15PM  
Aug-08-19 03:00PM  
11:15AM  
07:05AM  
Jul-12-19 01:32PM  
Jul-10-19 05:51PM  
Jul-03-19 05:00PM  
Jun-26-19 02:12PM  
Jun-17-19 08:05AM  
Jun-13-19 07:04PM  
Jun-12-19 08:05AM  
Jun-10-19 11:42PM  
06:39PM  
May-29-19 08:05AM  
May-28-19 08:05AM  
May-24-19 09:16AM  
May-23-19 08:17AM  
May-15-19 08:05AM  
May-13-19 04:25PM  
03:00PM  
10:47AM  
09:51AM  
09:32AM  
May-10-19 03:55PM  
03:00PM  
02:40PM  
11:40AM  
10:33AM  
09:05AM  
May-09-19 04:52PM  
04:20PM  
03:35PM  
03:00PM  
01:23PM  
12:45PM  
11:50AM  
09:28AM  
09:15AM  
08:04AM  
May-08-19 10:00PM  
09:00PM  
06:54PM  
03:35PM  
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Millian Craig StuartChief Commercial OfficerMar 17Buy4.252,0008,50012,000Mar 18 01:18 PM
Cohen YuvalChief Executive OfficerMar 17Buy3.494,30015,00771,090Mar 17 01:14 PM
Discordia Robert PaulChief Operating OfficerMar 17Buy3.542,84010,05435,490Mar 18 11:21 AM
White BarbaraChief Medical OfficerMar 17Buy3.6315,60656,650206,217Mar 18 10:37 AM
White BarbaraChief Medical OfficerNov 12Buy4.383,42414,992190,611Nov 13 10:00 AM
Cohen YuvalChief Executive OfficerNov 12Buy4.261,4306,09266,790Nov 12 01:02 PM
Millian Craig StuartChief Commercial OfficerNov 11Buy4.381,0004,38010,000Nov 12 11:07 AM
Discordia Robert PaulChief Operating OfficerNov 11Buy4.622,50011,55932,650Nov 12 09:57 AM
Millian Craig StuartChief Commercial OfficerAug 15Buy5.481,5008,2139,000Aug 16 09:50 AM
Cohen YuvalChief Executive OfficerAug 12Buy6.061,1757,11665,360Aug 12 10:37 AM
Discordia Robert PaulChief Operating OfficerAug 12Buy5.8615,00087,89430,150Aug 12 10:18 AM
White BarbaraChief Medical OfficerAug 12Buy6.101,6399,998187,187Aug 13 11:46 AM
Millian Craig StuartChief Commercial OfficerAug 12Buy6.001,5009,0007,500Aug 13 09:48 AM